Targeting immunometabolic pathways with AZD1656 alleviates inflammation and metabolic dysfunction in type 2 diabetic cardiomyopathy.
期刊:Nature Cardiovascular Research
影响因子:10.800
doi:10.1038/s44161-025-00769-0
Anderson Stephanie, Karlstaedt Anja, Young Megan, Karatzia Loucia, Cullen Fenn, Chen Jianmin, O'Riordan Caroline E, Barnes Michael R, Å taka Zorana, Albee Lauren J, Garrod-Ketchley Conor, Dambure Sanushi, Prag Hiran A, Cvetko Filip, Miller Jack J J J, Thiemermann Christoph, Lewis Andrew J M, Murphy Michael P, Smith David M, Henson Sian M, Tyler Damian J, Aksentijevic Dunja